

CBD SUMMIT: A NATIONAL DIALOGUE ON PUBLIC SAFETY, RESEARCH, AND POLICY

Wednesday, January 15, 2020 | Washington, DC | #CBDPolicySummit

ATTENDANCE

The Summit involved more than 125 total attendees including patient advocates, healthcare providers, professional organizations, industry groups, and leaders from U.S. federal agencies and Congress. Staff from local and national press and trade publications also attended. The CBD Summit marked an important moment as the first major event to convene a far-reaching array of interested stakeholder groups together to discuss the importance of ensuring the quality and safety of CBD and CBD-derived products available for consumer use.

“I want a patient to get something that helps them as soon as possible – but we better be sure it works. Otherwise, we create false hope.”

– U.S. Congressman Andy Harris, M.D. (MD-01)



KEY DISCUSSIONS



Summit attendees heard from policy leaders including Congressman Andy Harris (MD-01) and FDA Principal Deputy Commissioner Dr. Amy Abernethy. Congressional staff from the Senate Health, Education, Labor, and Pensions (HELP) and House Energy & Commerce Committees expanded on Representative Harris’ earlier remarks, discussing where Congress is headed on CBD regulation and oversight, and highlighting a hearing held earlier in the day on the future of cannabis and cannabidiol regulation and policy.

Summit presentations emphasized the need for immediate FDA action. Speakers highlighted many concerns related to the CBD market and products, including:

1. The many bad actors in the marketplace profiting off patients’ seeking treatment or other unproven benefits;
2. The lack of trustworthy information about what is products currently marketed as CBD;
3. Patients’ belief that over-the-counter CBD products are a safe to substitute to FDA-approved treatment; and
4. Continued the high consumer demand for CBD products.



“As an agency, we have a responsibility to be clear about what high quality looks like.”

– Amy Abernethy, MD, PhD, FDA Principal Deputy Commissioner for Food and Drugs

“THE TIME TO ACT WAS A YEAR AGO, BUT WE WILL SETTLE FOR NOW.”

– Steve Mister, JD, CAE, President & CEO, Council for Responsible Nutrition

Thank you for joining us for an impactful dialogue. Please contact [Libby Baney](#) or [Matthew Rubin](#) with any follow-up to the CBD Summit. We look forward to continued opportunities to promote policies that prioritize public health and patient safety.

A special thanks to our Summit Co-Conveners:

